Key facts
- This page summarizes Pawel Lewicki's Form 4 filing for SURGALIGN HOLDINGS, INC..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 28 Jan 2022, 14:18.
Pawel Lewicki - 26 Jan 2022 Form 4 Insider Report for SURGALIGN HOLDINGS, INC.
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 26 Jan 2022
- Net transaction value
- +$3,403,537
- SEC form
- 4
- Accepted by SEC
- 28 Jan 2022, 14:18:46 UTC
- Prior SEC filing
- 04 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- By Jessica Rumschlag as attorney in fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Pawel Lewicki filed Form 4 for SURGALIGN HOLDINGS, INC. on 28 Jan 2022.
Change
- Previous filing in this sequence was filed on 04 Jan 2022.
- Current net transaction value: +$3,403,537.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SRGA
transaction
Common Stock
Award
- Transaction value
- $3,403,537
- Shares
- +4,973,750
- Change %
- +239%
- Price
- $0.6843
- Shares after
- 7,058,385
- Date
- 26 Jan 2022
- Ownership
- Direct
- Footnotes
- F1
SRGA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,250,000
- Date
- 26 Jan 2022
- Ownership
- Roboticine, Inc
- Footnotes
- F2
SRGA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,410,396
- Date
- 26 Jan 2022
- Ownership
- By Neva, LLC
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
On January 26, 2022, the reporting person became entitled to receive 4,973,750 shares of common stock of Surgalign Holdings, Inc. (the "Company") pursuant to an "earn-out" provision in the stock purchase agreement pursuant to which the Company acquired the outstanding equity interests of Holo Surgical Inc. on October 23, 2020. The agreement provided that the reporting person would receive additional shares of common stock of the Company, for no additional consideration, based on the achievement of certain milestones. The first milestone was satisfied, as a result of which the reporting person became entitled to receive the additional shares. The number of shares issuable pursuant to the earn-out right was determined on January 26, 2022, pursuant to a formula set forth in the stock purchase agreement. The right to receive additional shares became fixed and irrevocable on October 23, 2020, the date of the acquisition of Holo Surgical Inc. by the Company.
Footnote F2
These shares of common stock are held by Roboticine, Inc, in which the reporting person indirectly holds a majority of the outstanding ownership interests. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Footnote F3
These shares of common stock are held by Neva, LLC, in which the reporting person holds all of the outstanding ownership interests.